NET ASSET VALUE – 30 June 2025
On the 30 June 2025 Flerie AB's Net Asset Value (NAV) was SEK 4,121 million and NAV per share was SEK 52.78.
|
Allocation of NAV |
Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 458 | 5.86 | 11.1% |
| Xspray Pharma | 18% | 326 | 4.18 | 7.9% |
| Empros Pharma | 79% | 204 | 2.62 | 5.0% |
| Atrogi | 44% | 197 | 2.52 | 4.8% |
| KAHR Medical | 31% | 180 | 2.30 | 4.4% |
| Lipum | 57% | 174 | 2.23 | 4.2% |
| Xintela | 59% | 165 | 2.12 | 4.0% |
| Microbiotica | 10% | 130 | 1.67 | 3.2% |
| Mendus | 23% | 92 | 1.18 | 2.2% |
| Geneos Therapeutics | 12% | 91 | 1.17 | 2.2% |
| AnaCardio | 13% | 79 | 1.02 | 1.9% |
| Toleranzia | 53% | 69 | 0.89 | 1.7% |
| Synerkine Pharma | 44% | 59 | 0.76 | 1.4% |
| EpiEndo Pharmaceuticals | 9% | 55 | 0.71 | 1.3% |
| Vitara Biomedical | 11% | 47 | 0.61 | 1.2% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.40 | 0.8% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.7% |
| Egetis Therapeutics | 2% | 27 | 0.34 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.13 | 0.3% |
| Total | 2,453 | 31.42 | 59.5% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.59 | 4.9% |
| Symcel | 30% | 192 | 2.46 | 4.7% |
| Chromafora | 30% | 73 | 0.93 | 1.8% |
| Nanologica | 43% | 44 | 0.56 | 1.1% |
| Frontier Biosolutions | 2% | 18 | 0.24 | 0.4% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 545 | 6.99 | 13.2% | |
| Limited Partnerships, total | 96 | 1.23 | 2.3% | |
| Assets related to Portfolio companies | 278 | 3.56 | 6.8% | |
| Other assets and liabilities | 748 | 9.58 | 18.2% | |
| Net Asset Value | 4,121 | 52.78 | 100.0% | |